CEBIOTEX Information

CEBIOTEX leverages nanofiber engineering to develop new medicinal products in the form of implantable membranes that can be infused with multiple agents. The proprietary technology allows to produce biocompatible and biodegradable membranes without chemical interaction between the nanofiber polymer and the agent applied. It is protected by several patents in EU, USA and China, ensuring competitiveness of the company in the global pharmaceutical market. This versatile technology can be applied to multiple indications, and be optimized for a wide variety of drugs, offering a high potential to improve current therapeutic options. CEBIOTEX’s leading product, CEB-01, is a nanofiber membrane loaded with the chemotherapeutic drug SN-38. CEB-01 is placed over the surgical bed after surgeon’s removal of a tumour mass, and immediately starts delivering SN-38 locally. It is compatible with current standard of care, while offering a treatment option during a period of time when no other therapy can be administered (4 weeks right after surgery). The therapeutic aim is to tackle tumor recurrence after surgery, which is associated to an unfavorable prognosis. CEB-01 clinical development plan encompasses first-in-human phase I clinical trial for Soft Tissue Sarcoma in adult pacients (finished recruiting, interim results available), first-in-pediatrics phase II basket clincial trial for neuroblastoma and rare sarcoma paediatric patients (pending approval), and phase II clinical trial for pancreatic adenocarcoma in adult pacients (active recruiting). Cebiotex started its activity in 2015 as a spin-off of UPC and Hospital Sant Joan de Déu de Barcelona.